Drug treatment for cancer of the corpus uteri: Protracted stagnation or breakthrough expectation
The paper considers the specific features of the course and therapy of cancer of the corpus uteri on the basis of some clinical and biological characteristics of the tumor. The objective of ongoing and future clinical trials is to expand the arsenal of active drugs and to individualize therapy in pa...
Main Author: | E. V. Artamonova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2014-08-01
|
Series: | Опухоли женской репродуктивной системы |
Subjects: | |
Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/183 |
Similar Items
-
Refining Adjuvant Therapy for Endometrial Cancer: New Standards and Perspectives
by: Alessandra Giustozzi, et al.
Published: (2021-08-01) -
Adjuvant vaginal interventional radiotherapy
in early-stage non-endometrioid carcinoma
of corpus uteri: a systematic review
by: Francesca De Felice, et al.
Published: (2021-04-01) -
An update on adenomyosis uteri
by: Sze Ching Hong, et al.
Published: (2016-08-01) -
Retrospective Analysis of Molecular Markers in Endometrial Cancer: Single Center Experience
by: Cem Yagmur Ozdemir, et al.
Published: (2024-02-01) -
Tumor markers in the diagnosis of cancer of the corpus uteri (a review of literature)
by: D. B. Olkin, et al.
Published: (2014-07-01)